Study of mcla-129 for lung cancer with egfr and met changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug, MCLA-129, for people with advanced non-small cell lung cancer that has specific gene changes (EGFR and MET) and has stopped responding to standard treatments. The drug targets these changes to possibly slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced non-small cell lung cancer that has grown or spread despite standard treatments.
- For part of the study, you need to have a specific EGFR gene change and either a MET amplification or have already tried a MET inhibitor.
- You must have at least one tumor that can be measured on scans and be well enough to be up and about (ECOG 0-1).
- You must have acceptable blood test results and not have had a heart attack or stroke in the past 6 months.
- You must not have had certain other cancers in the last 3 years, except for fully treated skin or early-stage cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
This study tests a new drug called ABBV-1480 combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see if it works as well as or better than the current standard treatment, pembrolizumab (also known as Keytruda) with chemotherapy.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug combination (MCLA-129 and befotertinib) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if the combination can shrink tumors or slow their growth, especially after other treatments have stopped working.
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.